⌘K
Loading ticker…
As of 2026-08-24, Matinas BioPharma Holdings, Inc. (MTNB) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 25. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 16.4%, relative volume 0.06×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MTNB is in a stage 4 downtrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -53.7% / -68.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MTNB appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $20K notional.
Held by 1 ETFs · $20K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $20K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MTNB Jan avg: 5.89% median: 7.87% win: 75% σ: 10.71% n: 4 2022-04-12 → 2026-07-31 | MTNB Feb avg: 6.25% median: 0.84% win: 50% σ: 24.02% n: 4 2022-04-12 → 2026-07-31 | MTNB Mar avg: -8.35% median: -6.78% win: 0% σ: 7.25% n: 4 2022-04-12 → 2026-07-31 | MTNB Apr avg: 1.47% median: 13.65% win: 60% σ: 28.41% n: 5 2022-04-12 → 2026-07-31 | MTNB May avg: 3.82% median: 1.43% win: 60% σ: 28.24% n: 5 2022-04-12 → 2026-07-31 | MTNB Jun avg: -2.82% median: -3.30% win: 40% σ: 14.14% n: 5 2022-04-12 → 2026-07-31 | MTNB Jul avg: -8.52% median: -1.12% win: 40% σ: 24.91% n: 5 2022-04-12 → 2026-07-31 | MTNB Aug avg: -0.81% median: -30.74% win: 25% σ: 72.84% n: 4 2022-04-12 → 2026-07-31 (current) | MTNB Sep avg: -14.62% median: -17.27% win: 25% σ: 14.40% n: 4 2022-04-12 → 2026-07-31 | MTNB Oct avg: -4.52% median: -2.17% win: 50% σ: 65.05% n: 4 2022-04-12 → 2026-07-31 | MTNB Nov avg: -15.41% median: -9.86% win: 25% σ: 21.63% n: 4 2022-04-12 → 2026-07-31 | MTNB Dec avg: -15.95% median: -21.27% win: 25% σ: 12.72% n: 4 2022-04-12 → 2026-07-31 |